Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists

Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Bui, Kim Tam, Cooper, Wendy A., Kao, Steven, Boyer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111731/
https://www.ncbi.nlm.nih.gov/pubmed/30065223
http://dx.doi.org/10.3390/jcm7080192
_version_ 1783350718364647424
author Bui, Kim Tam
Cooper, Wendy A.
Kao, Steven
Boyer, Michael
author_facet Bui, Kim Tam
Cooper, Wendy A.
Kao, Steven
Boyer, Michael
author_sort Bui, Kim Tam
collection PubMed
description Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC.
format Online
Article
Text
id pubmed-6111731
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61117312018-08-28 Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists Bui, Kim Tam Cooper, Wendy A. Kao, Steven Boyer, Michael J Clin Med Review Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific anti-cancer therapies to improve patient outcomes. New targeted molecular treatments are constantly being developed and evaluated as a means to improve efficacy, overcome resistance, or minimise toxicity. This review article summarises the current evidence for the efficacy, resistance mechanisms, and safety of targeted molecular treatments against specific mutations in NSCLC. MDPI 2018-07-31 /pmc/articles/PMC6111731/ /pubmed/30065223 http://dx.doi.org/10.3390/jcm7080192 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bui, Kim Tam
Cooper, Wendy A.
Kao, Steven
Boyer, Michael
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
title Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
title_full Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
title_fullStr Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
title_full_unstemmed Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
title_short Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
title_sort targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111731/
https://www.ncbi.nlm.nih.gov/pubmed/30065223
http://dx.doi.org/10.3390/jcm7080192
work_keys_str_mv AT buikimtam targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists
AT cooperwendya targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists
AT kaosteven targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists
AT boyermichael targetedmoleculartreatmentsinnonsmallcelllungcanceraclinicalguideforoncologists

Ejemplares similares